On April 20, 2020 Phost’in Therapeutics (Montpellier, France), a biopharmaceutical company focused on the discovery and development of N-glycosylation inhibitors, reported that it has successfully secured a €10.3 million Series A round, from an international syndicate of LifeScience and Innovation Investors led by Remiges Ventures and completed by ANRI and IrdiSoridec (Press release, Phost’in, APR 20, 2020, View Source [SID1234560965]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!